-- Scott Roberts
MONDAY, Sept. 19 (HealthDay News) -- The U.S. Food and Drug
Administration has expanded approval for the Amgen bone-building
drug Prolia (denosumab) to include prostate cancer or breast cancer
patients who are taking certain hormonal therapies.
The drug was initially approved in 2010 to help prevent
osteoporosis in post-menopausal women.
Breast cancer patients who use a class of hormone therapy known
as aromatase inhibitors to limit estrogen production, and prostate
cancer patients who are treated with hormones that limit production
of androgens (including testosterone), may be at greater risk of
Amgen is based in Thousand Oaks, Calif.
The FDA has
more about this drug.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.